JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:
A live webcast of the Baird and HC Wainwright presentations will be available on the Investors section of the Company's website: www.scynexis.com. Replay of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsNatalie WildenradtArgot PartnersTel: email@example.com
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-upcoming-investor-conferences-300701931.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All